These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 34787883)
1. Acute severe SARS COVID-19 patients produce pro-resolving lipids mediators and eicosanoids. Regidor PA; De La Rosa X; Santos FG; Rizo JM; Gracia Banzo R; Silva RS Eur Rev Med Pharmacol Sci; 2021 Nov; 25(21):6782-6796. PubMed ID: 34787883 [TBL] [Abstract][Full Text] [Related]
2. Quantitative profiling of inflammatory and pro-resolving lipid mediators in human adolescents and mouse plasma using UHPLC-MS/MS. Hartling I; Cremonesi A; Osuna E; Lou PH; Lucchinetti E; Zaugg M; Hersberger M Clin Chem Lab Med; 2021 Oct; 59(11):1811-1823. PubMed ID: 34243224 [TBL] [Abstract][Full Text] [Related]
3. PCOS: A Chronic Disease That Fails to Produce Adequately Specialized Pro-Resolving Lipid Mediators (SPMs). Regidor PA; de la Rosa X; Müller A; Mayr M; Gonzalez Santos F; Gracia Banzo R; Rizo JM Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203665 [TBL] [Abstract][Full Text] [Related]
4. High levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients. Archambault AS; Zaid Y; Rakotoarivelo V; Turcotte C; Doré É; Dubuc I; Martin C; Flamand O; Amar Y; Cheikh A; Fares H; El Hassani A; Tijani Y; Côté A; Laviolette M; Boilard É; Flamand L; Flamand N FASEB J; 2021 Jun; 35(6):e21666. PubMed ID: 34033145 [TBL] [Abstract][Full Text] [Related]
5. The function of specialized pro-resolving endogenous lipid mediators, vitamins, and other micronutrients in the control of the inflammatory processes: Possible role in patients with SARS-CoV-2 related infection. Gallo CG; Fiorino S; Posabella G; Antonacci D; Tropeano A; Pausini E; Pausini C; Guarniero T; Hong W; Giampieri E; Corazza I; Loiacono R; Loggi E; de Biase D; Zippi M; Lari F; Zancanaro M Prostaglandins Other Lipid Mediat; 2022 Apr; 159():106619. PubMed ID: 35032665 [TBL] [Abstract][Full Text] [Related]
6. Pro-Resolving Lipid Mediators in the Pathophysiology of Asthma. Kytikova O; Novgorodtseva T; Denisenko Y; Antonyuk M; Gvozdenko T Medicina (Kaunas); 2019 Jun; 55(6):. PubMed ID: 31216723 [TBL] [Abstract][Full Text] [Related]
7. Possibility of averting cytokine storm in SARS-COV 2 patients using specialized pro-resolving lipid mediators. Yasmeen N; Selvaraj H; Lakhawat SS; Datta M; Sharma PK; Jain A; Khanna R; Srinivasan J; Kumar V Biochem Pharmacol; 2023 Mar; 209():115437. PubMed ID: 36731803 [TBL] [Abstract][Full Text] [Related]
9. Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. Colas RA; Shinohara M; Dalli J; Chiang N; Serhan CN Am J Physiol Cell Physiol; 2014 Jul; 307(1):C39-54. PubMed ID: 24696140 [TBL] [Abstract][Full Text] [Related]
10. Specialized Pro-Resolving Mediators in Neuroinflammation: Overview of Studies and Perspectives of Clinical Applications. Valente M; Dentoni M; Bellizzi F; Kuris F; Gigli GL Molecules; 2022 Jul; 27(15):. PubMed ID: 35956787 [TBL] [Abstract][Full Text] [Related]
11. The relationship between specialized pro-resolving lipid mediators, morbid obesity and weight loss after bariatric surgery. Schulte F; Asbeutah AA; Benotti PN; Wood GC; Still C; Bistrian BR; Hardt M; Welty FK Sci Rep; 2020 Nov; 10(1):20128. PubMed ID: 33208757 [TBL] [Abstract][Full Text] [Related]
12. Resolvins, Protectins, and Maresins: DHA-Derived Specialized Pro-Resolving Mediators, Biosynthetic Pathways, Synthetic Approaches, and Their Role in Inflammation. Ferreira I; Falcato F; Bandarra N; Rauter AP Molecules; 2022 Mar; 27(5):. PubMed ID: 35268778 [TBL] [Abstract][Full Text] [Related]
13. Serum lipid mediator profiles in COVID-19 patients and lung disease severity: a pilot study. Irún P; Gracia R; Piazuelo E; Pardo J; Morte E; Paño JR; Boza J; Carrera-Lasfuentes P; Higuera GA; Lanas A Sci Rep; 2023 Apr; 13(1):6497. PubMed ID: 37081104 [TBL] [Abstract][Full Text] [Related]
14. Can Bioactive Lipids Inactivate Coronavirus (COVID-19)? Das UN Arch Med Res; 2020 Apr; 51(3):282-286. PubMed ID: 32229155 [TBL] [Abstract][Full Text] [Related]
15. Role of specialized pro-resolving lipid mediators and their receptors in virus infection: a promising therapeutic strategy for SARS-CoV-2 cytokine storm. Lee CH Arch Pharm Res; 2021 Jan; 44(1):84-98. PubMed ID: 33398691 [TBL] [Abstract][Full Text] [Related]
16. Metabolomics-lipidomics of eicosanoids and docosanoids generated by phagocytes. Yang R; Chiang N; Oh SF; Serhan CN Curr Protoc Immunol; 2011 Nov; Chapter 14():Unit 14.26. PubMed ID: 22048801 [TBL] [Abstract][Full Text] [Related]
17. Pro resolving inflammatory effects of the lipid mediators of omega 3 fatty acids and its implication in SARS COVID-19. Regidor PA; Santos FG; Rizo JM; Egea FM Med Hypotheses; 2020 Dec; 145():110340. PubMed ID: 33069094 [TBL] [Abstract][Full Text] [Related]
18. Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation. Norris PC; Skulas-Ray AC; Riley I; Richter CK; Kris-Etherton PM; Jensen GL; Serhan CN; Maddipati KR Sci Rep; 2018 Dec; 8(1):18050. PubMed ID: 30575798 [TBL] [Abstract][Full Text] [Related]
19. Randomized placebo-controlled intervention with n-3 LC-PUFA-supplemented yoghurt: effects on circulating eicosanoids and cardiovascular risk factors. Dawczynski C; Massey KA; Ness C; Kiehntopf M; Stepanow S; Platzer M; Grün M; Nicolaou A; Jahreis G Clin Nutr; 2013 Oct; 32(5):686-96. PubMed ID: 23332800 [TBL] [Abstract][Full Text] [Related]
20. Chemokines and eicosanoids fuel the hyperinflammation within the lungs of patients with severe COVID-19. Zaid Y; Doré É; Dubuc I; Archambault AS; Flamand O; Laviolette M; Flamand N; Boilard É; Flamand L J Allergy Clin Immunol; 2021 Aug; 148(2):368-380.e3. PubMed ID: 34111453 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]